Ribes J A, Francis C W
Department of Medicine, University of Rochester School of Medicine & Dentistry, NY.
Blood. 1990 Apr 1;75(7):1460-5.
von Willebrand factor (vWF) is synthesized in endothelial cells (EC) and may be either secreted constitutively or stored in Weibel-Palade bodies (WPB) for regulated release. Because fibrin stimulates rapid vWF release from EC, we examined the binding of EC synthesized vWF to fibrin. Culture medium containing constitutively secreted vWF was removed from metabolically labeled primary cultures of human umbilical vein EC, and vWF released from WPB was obtained after stimulation by A23187. vWF-deficient fibrinogen with or without factor XIII was added to releasate or media and clotted with thrombin to form crosslinked or noncrosslinked fibrin. vWF was immunopurified from releasate or media before and after clotting, and the amount and multimeric pattern of vWF bound was determined after sodium dodecyl sulfate agarose gel electrophoresis. High molecular weight multimers of vWF, whether secreted constitutively or released from WPB, bound preferentially to fibrin. Multimers of greater than 20 subunits represented 60% +/- 4% (SEM) of A23187 released vWF and 11% +/- 5% of media vWF, but binding to fibrin was similar, 96% +/- 1% and 94% +/- 2%, respectively. A progressively smaller proportion of vWF bound as multimer size decreased, and dimeric vWF binding was least, with 34% +/- 5% binding from A23187 releasate and 51% +/- 4% from media. The amount of vWF binding to crosslinked or noncrosslinked fibrin was similar, and preferential binding of high molecular weight multimers occurred with both. As measured by enzyme-linked immunosorbent assay, 45% +/- 2% of constitutively secreted vWF bound to crosslinked fibrin and 50% +/- 2% to noncrosslinked fibrin. The propolypeptide of vWF did not bind to fibrin. These findings indicate that binding of EC secreted vWF binding to fibrin depends on multimeric size but not on factor XIII crosslinking. This suggests that vWF released from EC in the presence of fibrin will bind locally, thereby facilitating platelet adhesion to the hemostatic plug or thrombus.
血管性血友病因子(vWF)在内皮细胞(EC)中合成,既可以组成性分泌,也可以储存于魏尔-帕拉德小体(WPB)中以供调节性释放。由于纤维蛋白可刺激vWF从EC快速释放,我们研究了EC合成的vWF与纤维蛋白的结合情况。从代谢标记的人脐静脉EC原代培养物中去除含有组成性分泌vWF的培养基,并在A23187刺激后获得从WPB释放的vWF。将含或不含因子XIII的vWF缺陷型纤维蛋白原添加到释放物或培养基中,并用凝血酶使其凝固以形成交联或非交联纤维蛋白。在凝血前后从释放物或培养基中免疫纯化vWF,并在十二烷基硫酸钠琼脂糖凝胶电泳后测定结合的vWF的量和多聚体模式。vWF的高分子量多聚体,无论组成性分泌还是从WPB释放,都优先与纤维蛋白结合。大于20个亚基的多聚体占A23187释放的vWF的60%±4%(SEM)和培养基vWF的11%±5%,但与纤维蛋白的结合相似,分别为96%±1%和94%±2%。随着多聚体大小减小,结合的vWF比例逐渐变小,二聚体vWF的结合最少,A23187释放物中有34%±5%的结合,培养基中有51%±4%的结合。vWF与交联或非交联纤维蛋白的结合量相似,且两者都有高分子量多聚体的优先结合。通过酶联免疫吸附测定法测量,组成性分泌的vWF中有45%±2%与交联纤维蛋白结合,50%±2%与非交联纤维蛋白结合。vWF的前肽不与纤维蛋白结合。这些发现表明,EC分泌的vWF与纤维蛋白的结合取决于多聚体大小,而不取决于因子XIII交联。这表明在纤维蛋白存在的情况下从EC释放的vWF将在局部结合,从而促进血小板粘附于止血栓或血栓。